Health
Semaglutide Shows Promise in Treating Serious Liver Condition, New Study Finds
A widely used ingredient in popular weight-loss drugs has shown promising results in treating a progressive liver condition for which no medications are currently approved in the European Union, according to a major new study published in the New England Journal of Medicine.
The clinical trial, funded by Danish pharmaceutical giant Novo Nordisk, found that semaglutide – the active compound in the blockbuster drugs Ozempic and Wegovy – significantly improved outcomes for patients suffering from metabolic dysfunction-associated steatohepatitis (MASH). The disease, which causes fat accumulation, inflammation, and scarring in the liver, is associated with obesity, type 2 diabetes, and high blood pressure and can progress to cirrhosis if left untreated.
The 72-week trial involved 800 participants with MASH and moderate to advanced liver fibrosis. Patients who received weekly injections of semaglutide showed notable improvements, with 33 percent experiencing reductions in both liver inflammation and scarring, compared to just 16 percent in the placebo group. Separately, 63 percent saw a decrease in liver inflammation, and 37 percent showed improved scarring. The placebo group showed improvements of 34 percent and 22 percent, respectively.
Participants taking semaglutide also lost an average of 10.5 percent of their body weight, reinforcing the drug’s potential dual benefit in treating both liver disease and obesity-related complications.
Professor Debbie Shawcross, a liver specialist at King’s College London and vice secretary general of the European Association for the Study of the Liver, called the findings “hugely exciting,” but cautioned that semaglutide alone may not be responsible for all the improvements. Participants across both treatment arms received lifestyle counseling and support in managing related health conditions, suggesting that behavior changes also played a significant role.
“This is important as any therapy that is licensed for MASH with moderate to severe fibrosis must be used in conjunction with lifestyle interventions,” Shawcross noted.
While semaglutide showed promise, some patients reported gastrointestinal side effects, including nausea, vomiting, and diarrhea. Around 2.6 percent of those on the drug withdrew from the study due to adverse effects.
Novo Nordisk, which announced the trial’s topline results in late 2024, has stated it plans to seek regulatory approval for semaglutide as a MASH treatment in both the EU and US by mid-2025. If approved, it would become the first such therapy available in Europe.
The move comes as the EU is also reviewing other experimental treatments for MASH, including resmetirom, which was approved in the US last year after showing positive results in reducing liver scarring.
While Shawcross said it is “too early to call” semaglutide a game-changer, she emphasized its potential if used alongside comprehensive lifestyle programs. However, she warned that many patients taking weight-loss drugs do not make lasting changes, raising concerns about the long-term impact once the medication is stopped.
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Home Improvement1 year agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
